Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea Reveals More On Plans To Grow Bioclusters At Osong And Daegu

This article was originally published in PharmAsia News

Executive Summary

SEOUL - The Korean government announced more details on how it plans to cultivate its multibillion dollar, high-tech pharmaceutical R&D projects in Osong and Daegu

You may also be interested in...



Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV

SEOUL - South Korea's leading conglomerate Samsung Group is following in the footsteps of Korea's biosimilar front-runner Celltrion in beginning its biopharmaceutical journey as a contract manufacturing organization via a joint venture announced Jan. 25 with multinational contract research organization Quintiles Transnational Corp.

And The Winner Is? Two Cities For The Price Of One Win Bid For Multi-billion Dollar Korean Biopolis

SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs named two cities - Osong and Daegu - as the winners of multi-billion-dollar, high-tech medical center sites planned in the country to draw multinational companies to the country

South Korea Will Not Pursue Compulsory Licensing Against MNCs, But For How Long?

SEOUL - The South Korean government currently has no plans to implement compulsory licensing to help rein in costs for Korean patients being treated for fatal diseases, but will reconsider its stance should negotiations with industry break down, Jeon Jae-Hee, the Minister for Health, Welfare and Family Affairs said Feb. 23

Related Content

UsernamePublicRestriction

Register

SC077459

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel